# To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses

> **NCT01469923** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 18 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** AZD2820
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01469923
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469923, "To Assess the Safety, Tolerability, Pharmacokinetics and Pharmakodynamics of AZD2820 After Multiple Ascending Doses". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01469923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*